S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
Buy THIS stock before Taiwan is attacked (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
Buy THIS stock before Taiwan is attacked (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
Buy THIS stock before Taiwan is attacked (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
Buy THIS stock before Taiwan is attacked (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software" (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
CVE:AQS

Aequus Pharmaceuticals (AQS) Stock Forecast, Price & News

C$0.02
-0.01 (-16.67%)
(As of 05/24/2023 05:22 PM ET)
Compare
Today's Range
C$0.03
▼
C$0.03
50-Day Range
C$0.03
▼
C$0.03
52-Week Range
C$0.02
▼
C$0.08
Volume
5,000 shs
Average Volume
120,141 shs
Market Capitalization
C$3.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsInsider TradesHeadlines

AQS stock logo

About Aequus Pharmaceuticals (CVE:AQS) Stock

Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Evolve dry eye products for various symptoms involved with dry eye disease and blepharitis, including discomfort, stinging, burning, and dryness; and preservative free ophthalmic product. Its development stage product includes Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.

Receive AQS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aequus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AQS Stock News Headlines

May 2, 2023 | finance.yahoo.com
Aequus Provides General Update and Fiscal 2022 Financial Results
April 19, 2023 | finance.yahoo.com
Aequus Grants Stock Options
May 27, 2023 | Behind the Markets (Ad)
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser
Small cap wins $1.65 billion contract to make them. GlobeNewswire says this is a $51.1 Billion market by 2026. See why this stock could soar 2,476% >>>
April 5, 2023 | finance.yahoo.com
Aequus Announces Financing to Support Launch of Zimed Preservative Free (Bimatoprost 0.03%) and Board Update
March 26, 2023 | finance.yahoo.com
Aequus Pharmaceuticals Inc. (AQS.V)
December 20, 2022 | finance.yahoo.com
Aequus Announces Health Canada Notice of Compliance (NOC) for Zimed® Preservative Free (Bimatoprost 0.03%)
December 3, 2022 | yahoo.com
Aequus Pharmaceuticals Third Quarter 2022 Earnings: CA$0.004 loss per share (vs CA$0.003 loss in 3Q 2021)
November 30, 2022 | finanznachrichten.de
Aequus Pharmaceuticals: Aequus Reports Third Quarter 2022 Financial Highlights
May 27, 2023 | Behind the Markets (Ad)
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser
Small cap wins $1.65 billion contract to make them. GlobeNewswire says this is a $51.1 Billion market by 2026. See why this stock could soar 2,476% >>>
November 30, 2022 | finance.yahoo.com
Aequus Reports Third Quarter 2022 Financial Highlights
November 29, 2022 | finance.yahoo.com
Aequus Announces Sandoz Contract Expiry at Year End and Expected Health Canada Approval for Zimed® PF (Preservative Free)
October 9, 2022 | reuters.com
Aequus Pharmaceuticals Inc
August 30, 2022 | seekingalpha.com
Aequus Pharmaceuticals reports Q2 results
August 29, 2022 | finance.yahoo.com
Aequus Reports Second Quarter 2022 Financial Highlights and General Update
July 13, 2022 | finance.yahoo.com
IIROC Trading Resumption - AQS
July 13, 2022 | finance.yahoo.com
Aequus Resumes Trading on TSX Venture Exchange
July 1, 2022 | financialpost.com
Aequus Provides General Update and Reports Record 2021 Financial Results
May 7, 2022 | stockhouse.com
Aequus Provides Update on Delay in Filing Annual Financial Statements
May 2, 2022 | finance.yahoo.com
IIROC Trading Halt - AQS.WT
May 2, 2022 | finance.yahoo.com
IIROC Trading Halt - AQS.DB
May 2, 2022 | stockhouse.com
Aequus Announces Short Term Loan
April 22, 2022 | benzinga.com
Aequus Announces Director Resignation
January 11, 2022 | finance.yahoo.com
Sandoz and Aequus Agree to 1-Year Extension on Vistitan in Canada
January 6, 2022 | finance.yahoo.com
Aequus Announces Canadian Filing of NDS for Preservative-Free Glaucoma Medication
November 5, 2021 | ca.finance.yahoo.com
Is Aequus Pharmaceuticals (CVE:AQS) Weighed On By Its Debt Load?
November 3, 2021 | apnews.com
Aequus Reports Third Quarter 2021 Financial Highlights
August 30, 2021 | stockhouse.com
Aequus Reports Second Quarter 2021 Financial Highlights
See More Headlines
Receive AQS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aequus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AQS Company Calendar

Today
5/27/2023
Next Earnings (Estimated)
6/29/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
CVE
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
CVE:AQS
CUSIP
N/A
CIK
N/A
Web
www.aequuspharma.ca
Phone
+1-604-3367906
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
C($0.02)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
C$-3,210,000.00
Net Margins
-232.65%
Pretax Margin
N/A
Return on Equity
-1,569.60%
Return on Assets
-53.45%

Debt

Debt-to-Equity Ratio
138.88
Current Ratio
0.38
Quick Ratio
0.46

Sales & Book Value

Annual Sales
C$1.38 million
Price / Sales
2.40
Cash Flow
C$0.01 per share
Price / Cash Flow
5.00
Book Value
C($0.01) per share
Price / Book
-2.50

Miscellaneous

Outstanding Shares
132,630,000
Free Float
N/A
Market Cap
C$3.32 million
Optionable
Not Optionable
Beta
0.53

Key Executives

  • Mr. Douglas Glen Janzen (Age 54)
    Chairman, CEO & Pres
    Comp: $225k
  • Ms. Ann Fehr CGA (Age 54)
    CPA, CFO & Corp. Sec.
    Comp: $155.94k
  • Mr. Stuart Fowler
    Strategic Commercial Advisor & Independent Director
  • Mr. Grant Larsen
    Chief Commercial Officer

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













AQS Stock - Frequently Asked Questions

How have AQS shares performed in 2023?

Aequus Pharmaceuticals' stock was trading at C$0.04 on January 1st, 2023. Since then, AQS stock has decreased by 28.6% and is now trading at C$0.03.
View the best growth stocks for 2023 here.

When is Aequus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, June 29th 2023.
View our AQS earnings forecast.

What other stocks do shareholders of Aequus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aequus Pharmaceuticals investors own include GrowLife (PHOT), Unrivaled Brands (TRTC), Abbott Laboratories (ABT), Acorn Energy (ACFN), Crown Castle (CCI), Charlotte's Web (CWBHF), (FIRE.V) (FIRE), LiCo Energy Metals (LIC), Marijuana Company of America (MCOA) and Planet 13 (PLNHF).

What is Aequus Pharmaceuticals' stock symbol?

Aequus Pharmaceuticals trades on the Canadian Venture Exchange (CVE) under the ticker symbol "AQS."

How do I buy shares of Aequus Pharmaceuticals?

Shares of AQS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Aequus Pharmaceuticals' stock price today?

One share of AQS stock can currently be purchased for approximately C$0.03.

How much money does Aequus Pharmaceuticals make?

Aequus Pharmaceuticals (CVE:AQS) has a market capitalization of C$3.32 million and generates C$1.38 million in revenue each year. The company earns C$-3,210,000.00 in net income (profit) each year or C($0.02) on an earnings per share basis.

How can I contact Aequus Pharmaceuticals?

Aequus Pharmaceuticals' mailing address is 2820-200 Granville St, VANCOUVER, BC V6C 1S4, Canada. The official website for the company is www.aequuspharma.ca. The company can be reached via phone at +1-604-3367906.

This page (CVE:AQS) was last updated on 5/27/2023 by MarketBeat.com Staff

My Account -